(Image source: Gemini / Landon Phillips) Chronic Kidney Disease (CKD) isn’t a single, sudden event; it’s a slow, progressive decline in kidney function. For decades, we’ve relied on staging systems to categorize this decline, helping doctors predict a patient’s future—whether they’re heading toward dialysis, or if they’re primarily at risk for a heart attack.
The backbone of this classification has been the KDIGO (Kidney Disease: Improving Global Outcomes) system. You likely know it: five categories (G1 through G5) based on the estimated Glomerular Filtration Rate (eGFR), which measures how well your kidneys are filtering waste.
But here’s the problem: relying solely on eGFR, or the G-stage, often painted an incomplete picture. Two people could have the exact same GFR, say G3a, but one might have minimal protein in their urine while the other is spilling massive amounts. Their prognoses, and their required treatments, are wildly different. Staging needed to become smarter, moving beyond just filtration speed to truly capture risk.
The Evolution of Staging: Integrating Albuminuria and GFR
The biggest leap in CKD staging came when clinicians started treating albuminuria—the amount of protein (specifically albumin) in the urine—as seriously as the GFR. This gave us the familiar CKD staging matrix, a grid where the G-stage (function) intersects with the A-stage (damage).
This combined staging system is the key to risk stratification. Albuminuria is categorized A1 (normal to mildly increased), A2 (moderately increased), and A3 (severely increased).
Think of the kidneys as a sieve. A low GFR (G4 or G5) means the sieve is clogged. But high albuminuria (A2 or A3) means the sieve is damaged and leaking key proteins. That damage, even if the GFR is still relatively good (G1 or G2), is a major red flag. Why? Because albuminuria is strongly linked to progressive kidney failure and to cardiovascular disease. If you’re in G2A3, you’re at a much higher risk of a heart event than someone in G3A1. The combined staging system forces clinicians to acknowledge that risk immediately.
Emerging Trends: Biomarkers Beyond Creatinine
If the integration of albuminuria was the first major upgrade to CKD staging, the latest KDIGO guidelines, finalized in 2024 and synthesized in 2025, represent the digital revolution in diagnostics². The biggest change is the push for better GFR estimation using biomarkers beyond standard creatinine.
For years, we’ve used serum creatinine to estimate GFR (eGFRcr). Creatinine is cheap and readily available, but it’s notoriously unreliable because it’s a product of muscle breakdown. If you’re a bodybuilder, your creatinine will be high, making your GFR look artificially low. If you’re elderly, frail, or malnourished (cachexia), your creatinine will be low, making your GFR look artificially high—masking serious kidney disease. Sound familiar?
The Cystatin C Advantage
Enter Cystatin C. This is a protein produced by almost all nucleated cells in the body, and its concentration in the blood is far less influenced by non-GFR determinants like muscle mass, diet, race, or age⁴.
The KDIGO 2024 guidelines now strongly recommend using a combined eGFR calculation (eGFRcr-cys) that incorporates both creatinine and Cystatin C, especially when available⁴. They consider this combined reading the most accurate non-invasive estimate, coming closest to the gold standard of measured GFR.
This isn’t just academic. For patients sitting on the borderline of CKD—specifically those with an eGFR between 45 and 59 mL/min/1.73 m^2—Cystatin C is important. It helps confirm if they truly have CKD (G3a) or if their slightly low creatinine-based GFR was just a statistical fluke⁵. Improved accuracy here means avoiding unnecessary worry or, conversely, starting life-saving treatments sooner.
Clinical Impact: How Improved Staging Changes Patient Management
So what does this improved, precision staging actually mean for you, the patient? It means faster, more aggressive, and more personalized medical intervention.
The latest staging clarity has directly influenced prescribing decisions, particularly concerning Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. These drugs, originally for diabetes, are now considered standard of care for cardiorenal protection in CKD patients, regardless of their diabetes status³.
The clinical evidence is a lot of: SGLT2 inhibitors reduce the risk of kidney failure, with studies showing a reduction in risk of about 34% (Hazard Ratio 0.66)¹⁰.
Although the recommendation to use SGLT2 inhibitors is broad, staging remains important for risk stratification. If your staging places you in a "Very High Risk" category (e.g., G4A3), your nephrologist knows you are a "Rapid Progressor" and needs combination therapy—likely an SGLT2 inhibitor paired with a nonsteroidal mineralocorticoid receptor antagonist like finerenone—immediately. The staging matrix tells the doctor the urgency of the situation.
Top Recommendations for High-Risk CKD Patients
The improved staging helps clinicians streamline the complex treatment pathways necessary for preserving kidney function and reducing cardiovascular risk.
- Early Intervention: Use eGFRcr-cys to confirm CKD stage, especially in borderline cases (eGFR 45–59).
- Goal-Directed Therapy: Initiate SGLT2 inhibitors and potentially MRAs (finerenone) based on the combined GFR and Albuminuria risk category.
- Risk Communication: Use risk calculators (like the Kidney Failure Risk Equation) alongside the CGA classification to clearly communicate the probability of needing dialysis or transplant within 2 or 5 years.
- Lifestyle Optimization: Aggressively manage blood pressure and glucose targets, which are often adjusted based on the specific CKD stage and associated risks.
The emphasis on precise staging also helps patient education. When you understand that your A-stage (albuminuria) is the primary driver of your heart risk, you’re more likely to adhere to medications and lifestyle changes aimed at reducing proteinuria.
The Future Space: Personalized CKD Trajectories
We’re moving away from viewing CKD staging as a static classification—like an address you never change—and toward a dynamic risk assessment tool. The ultimate goal for the 2025/2026 outlook is to predict individual progression trajectories.
This involves integrating the often-overlooked "C" in the CGA classification: Cause. The new guidelines are promoting the use of precision diagnostic tools, including genetic testing, to pinpoint the exact cause of CKD more frequently¹. If we know the exact molecular mechanism driving your disease, we can target it with unprecedented specificity.
KDIGO is pushing clinicians to use risk calculators that estimate a patient's likelihood of progressing to kidney failure within defined time frames (e.g., 2 to 5 years). This shift means that two people with G3a CKD might be treated entirely differently if one has a 50% risk of kidney failure in five years and the other has a 5% risk.
In essence, CKD staging is becoming an individualized roadmap. It’s no longer just about knowing where you are, but predicting exactly where you’re going and, importantly, providing the right therapeutic detours to keep you off the path to dialysis. For clinicians and patients alike, staying current with these changing protocols isn't just helpful—it’s absolutely necessary for getting the most from long-term outcomes.
Sources:
3. Experts update CKD guidelines
4. KDIGO CKD 2024 Guidelines on Cystatin C in Patients
This article is for informational and educational purposes only. Readers are encouraged to consult qualified professionals and verify details with official sources before making decisions. This content does not constitute professional advice.
.png)